Unlike serum prostate specific antigen (PSA) levels, PCA3 is not affected by the prostate volume or non-cancerous prostate hyperplasia, making it a particularly useful biomarker, especially for identifying patients with clinically insignificant prostate cancer [247,248,249,250,251]. This evidence concerns the gene KLK3 and prostate disorder.